Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am 2018 Jan;27(1):141-153
Date
11/15/2017Pubmed ID
29132557DOI
10.1016/j.soc.2017.08.004Scopus ID
2-s2.0-85034238097 (requires institutional sign-in at Scopus site) 100 CitationsAbstract
Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on improvement in pathologic complete response rates and outcomes of patients with residual disease.
Author List
Chaudhary LN, Wilkinson KH, Kong AAuthors
Lubna N. Chaudhary MD Associate Professor in the Medicine department at Medical College of WisconsinAmanda L. Kong MD, MS Professor in the Surgery department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsChemotherapy, Adjuvant
Female
Humans
Neoadjuvant Therapy
Triple Negative Breast Neoplasms